Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to IMAAVY® (nipocalimab-aahu), marking a significant milestone as the first therapy to receive this designation for warm autoimmune hemolytic anemia (wAIHA). The Priority Review designation, reported by PR Newswire, shortens the FDA’s standard review timeline to approximately six months, reflecting the urgent medical need in this life-threatening disease.
A Devastating Disease with No Approved Treatments
Warm autoimmune hemolytic anemia is a rare but serious condition affecting approximately 1-3 new people per 100,000 annually, with roughly 1 in 8,000 individuals currently living with the disease. In wAIHA, pathogenic immunoglobulin G (IgG) autoantibodies attach to and destroy red blood cells, leading to severe, debilitating anemia. The condition affects both men and women across all ages, with increased incidence over age 50.
Beyond anemia, wAIHA patients face heightened risks of serious complications including venous thrombotic events, acute renal failure, and infection. Currently, no FDA-approved medications exist specifically for wAIHA, leaving patients dependent on unapproved corticosteroids, broad immunosuppressants, and B-cell directed therapies—none of which address the underlying disease mechanism.
A Differentiated Approach
IMAAVY represents an innovative immunoselective treatment designed to target the underlying cause of wAIHA. Rather than using broad immunosuppression, IMAAVY blocks the neonatal Fc receptor (FcRn), reducing circulating IgG antibodies—including the pathogenic autoantibodies driving disease, while preserving critical immune functions. This targeted approach distinguishes IMAAVY from current treatment options by directly addressing the disease mechanism rather than broadly suppressing the immune system.
Pivotal Study Success
The Priority Review decision is supported by compelling results from the pivotal Phase 2/3 ENERGY trial. This multicenter, randomized, double-blind, placebo-controlled study demonstrated that more patients treated with IMAAVY achieved durable hemoglobin response compared with placebo. Specifically, durable hemoglobin response was defined as hemoglobin concentration ≥10 g/dL with an increase from baseline of ≥2 g/dL maintained for at least 28 days.
Beyond laboratory improvements, the trial showed significant fatigue improvement, a critical quality-of-life measure for patients struggling with the debilitating effects of severe anemia. These clinical outcomes underscore IMAAVY’s potential to meaningfully improve patients’ daily functioning and wellbeing.
Broader Development Pipeline
IMAAVY is already approved by the FDA for treating generalized myasthenia gravis (gMG) in adults and pediatric patients 12 years and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. Johnson & Johnson is investigating nipocalimab across multiple auto- and alloantibody-driven diseases, including rheumatologic conditions, rare autoantibody diseases, and maternal-fetal diseases.
The drug has received extensive regulatory recognition, including Fast Track designations for wAIHA, HDFN, and several other conditions, as well as Breakthrough Therapy designations for hemolytic disease of the fetus and newborn (HDFN) and Sjögren’s disease.
Looking Ahead
Dr. Leonard L. Dragone, Disease Area Leader for Autoantibody and Rheumatology at Johnson & Johnson, emphasized that this Priority Review designation reflects “both the serious, life-threatening nature of wAIHA and the potential for IMAAVY to help address a critical unmet need.” Full ENERGY trial results will be presented at an upcoming medical conference, providing the scientific community with comprehensive efficacy and safety data for this promising therapeutic approach.
